In the latest venture- American pharmaceutical company Bristol-Myers Squibb and Paris-based Voluntis have come together to design specialized programs for cancer patients through an innovative digital-therapeutic platform.
With the tool’s evidence-based algorithm, patients will be able to track their treatment and therapy based symptoms. In addition, they will also be able to seek information on self-management. Furthermore, with more information on their condition, cancer patients will be able to discuss more personalized health programs with providers. The algorithms will help in providing real-time guidance for therapy related symptoms.
Sources suggest Voluntis will work with New York based Bristol-Myers Squibb to create the Theraxium Oncology system. The system will largely be mobile centered apps for patients.
Bristol-Myers Squibb has worked diversely in the field of oncology drugs, the progress has especially been noteworthy after its acquisition last year of Celgene. Major highlights of therapies in development include CAR-T cells like lisocabtagene maraleucel for non-Hodgkin’s lymphoma and idecabtagene vicleucel for multiple myeloma.
Along with Bristol-Myers Squibb, Voluntis has current partnerships on oncology with AstraZeneca and Novartis. Voluntis’ digital therapeutic project with AstraZeneca, eCO was created for women with ovarian cancer in clinical trials of Lynparza (olaparib) combined with cediranib.
Market experts reveal such partnerships between biopharma and digital therapeutics companies have not been well received in the current market scenario. For instance, in October, Novartis withdrew a partnership deal with Pear Therapeutics, while Proteus Digital Health and Otsuka Pharmaceuticals also pulled out from a deal in January.